Toxic effects of acute glutathione depletion by buthionine sulfoximine and dimethylfumarate on murine mammary carcinoma cells. 1988

L A Dethlefsen, and C M Lehman, and J E Biaglow, and V M Peck
Department of Radiology, University of Utah Health Sciences Center, Salt Lake City 84132.

Glutathione (GSH) depletion to approximately equal to 5% of control for 48 h or longer by 0.05 mM L-buthionine sulfoximine (BSO) led to appreciable toxicity for the 66 murine mammary carcinoma cells growing in vitro [L.A. Dethlefsen et al., Int. J. Radiat. Oncol. Biol. Phys. 12, 1157-1160 (1986)]. Such toxicity in normal, proliferating cells in vivo would be undesirable. Thus the toxic effects after acute GSH depletion to approximately equal to 5% of control by BSO plus dimethylfumarate (DMF) were evaluated in these same 66 cells to determine if this anti-proliferative effect could be minimized. Two hours of 0.025 mM DMF reduced GSH to 45% of control, while 6 h of 0.05 mM BSO reduced it to 16%. However, BSO (6 h) plus DMF (2 h) and BSO (24 h) plus DMF (2 h) reduced GSH to 4 and 2%, respectively. The incorporation (15-min pulses) of radioactive precursors into protein and RNA were unaffected by these treatment protocols. In contrast, cell growth was only modestly affected, but the incorporation of [3H]thymidine into DNA was reduced to 64% of control by the BSO (24 h) plus DMF (2 h) protocol even though it was unaffected by the BSO (6 h) plus DMF (2 h) treatment. The cellular plating efficiencies from both protocols were reduced to approximately equal to 75% of control cells. However, the aerobic radiation response, as measured by cell survival, was not modified at doses of either 4.0 or 8.0 Gy. The growth rates of treated cultures, after drug removal, quickly returned to control rates and the resynthesis of GSH in cells from both protocols was also rapid. The GSH levels after either protocol were slightly above control by 12 h after drug removal, dramatically over control (approximately equal to 200%) by 24 h, and back to normal by 48 h. Thus even a relatively short treatment with BSO and DMF resulting in a GSH depletion to 2-5% of control had a marked effect on DNA synthesis and plating efficiency and a modest effect on cellular growth. One cannot rule out a direct effect of the drugs, but presumably the antiproliferative effects are due to a depletion of nuclear GSH with the subsequent inhibition of the GSH/glutaredoxin-mediated conversion of ribonucleotides to deoxyribonucleotides. However, even after extended treatment, upon drug removal, GSH was rapidly resynthesized and cellular DNA synthesis and growth quickly resumed.

UI MeSH Term Description Entries
D008325 Mammary Neoplasms, Experimental Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS. Experimental Mammary Neoplasms,Neoplasms, Experimental Mammary,Experimental Mammary Neoplasm,Mammary Neoplasm, Experimental,Neoplasm, Experimental Mammary
D008717 Methionine Sulfoximine Sulfoximine, Methionine
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003864 Depression, Chemical The decrease in a measurable parameter of a PHYSIOLOGICAL PROCESS, including cellular, microbial, and plant; immunological, cardiovascular, respiratory, reproductive, urinary, digestive, neural, musculoskeletal, ocular, and skin physiological processes; or METABOLIC PROCESS, including enzymatic and other pharmacological processes, by a drug or other chemical. Chemical Depression,Chemical Depressions,Depressions, Chemical
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005650 Fumarates Compounds based on fumaric acid. Fumarate,Fumaric Acid Ester,Fumaric Acid Esters,Fumarate Esters,Acid Ester, Fumaric,Acid Esters, Fumaric,Ester, Fumaric Acid,Esters, Fumarate,Esters, Fumaric Acid
D005978 Glutathione A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides. Reduced Glutathione,gamma-L-Glu-L-Cys-Gly,gamma-L-Glutamyl-L-Cysteinylglycine,Glutathione, Reduced,gamma L Glu L Cys Gly,gamma L Glutamyl L Cysteinylglycine
D000069462 Dimethyl Fumarate A fumarate derivative that is used as a DERMATOLOGIC AGENT in the treatment of PSORIASIS and SKIN DISEASES. It also may be used as an IMMUNOSUPPRESSIVE AGENT in the treatment of MULTIPLE SCLEROSIS. 2-butenedioic acid, (2E)-, dimethyl ester,BG 00012,BG 12 compound,BG-00012,BG-12 compound,BG00012,BG12 compound,Dimethylfumarate,FAG 201,FAG-201,FAG201,Fumaderm,Tecfidera,00012, BG,12 compound, BG,201, FAG,Fumarate, Dimethyl,compound, BG 12,compound, BG12

Related Publications

L A Dethlefsen, and C M Lehman, and J E Biaglow, and V M Peck
July 1986, International journal of radiation oncology, biology, physics,
L A Dethlefsen, and C M Lehman, and J E Biaglow, and V M Peck
May 1993, Cancer research,
L A Dethlefsen, and C M Lehman, and J E Biaglow, and V M Peck
June 1985, Radiation research,
L A Dethlefsen, and C M Lehman, and J E Biaglow, and V M Peck
July 1987, British journal of cancer,
L A Dethlefsen, and C M Lehman, and J E Biaglow, and V M Peck
June 2012, American journal of hypertension,
L A Dethlefsen, and C M Lehman, and J E Biaglow, and V M Peck
February 2006, Carcinogenesis,
L A Dethlefsen, and C M Lehman, and J E Biaglow, and V M Peck
September 1995, Research communications in molecular pathology and pharmacology,
L A Dethlefsen, and C M Lehman, and J E Biaglow, and V M Peck
January 1986, Investigational new drugs,
L A Dethlefsen, and C M Lehman, and J E Biaglow, and V M Peck
December 1988, The American review of respiratory disease,
L A Dethlefsen, and C M Lehman, and J E Biaglow, and V M Peck
December 1989, Urology,
Copied contents to your clipboard!